Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vioxx Cardiovascular Risk Is Unique To Molecule, Pfizer And Novartis Tell FDA

Executive Summary

The cardiovascular safety signal observed in Merck's Vioxx may be caused by the formation of potentially toxic rofecoxib metabolites, Pfizer states in its briefing documents for FDA's upcoming review of COX-2 inhibitors

You may also be interested in...



FDA Discloses Safety Reviews Of COX-2s Arcoxia, Prexige and Parecoxib

Merck's Arcoxia is linked to an increase in cardiovascular adverse events across multiple analyses, FDA reviewers state in briefing documents for the upcoming COX-2 inhibitor safety review

FDA Discloses Safety Reviews Of COX-2s Arcoxia, Prexige and Parecoxib

Merck's Arcoxia is linked to an increase in cardiovascular adverse events across multiple analyses, FDA reviewers state in briefing documents for the upcoming COX-2 inhibitor safety review

Bextra Use Suspended By Kaiser; Celebrex Alzheimer’s Data Under Scrutiny

A decision by Kaiser Permanente physicians in California to stop prescribing Bextra demonstrates the challenges Pfizer must overcome as it seeks to reassure the public about the cardiovascular safety of COX-2 inhibitors

Related Content

Topics

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel